

CLAIM AMENDMENTS

1 1. (currently amended) A therapeutic agent having a
2 destructive effect on malignant tumors which ~~[[is]]~~ comprises as
3 therapeutically effective ingredients: substances of alpha-
4 ketoglutaric acid or its pharmaceutically effective salts and at
5 least one compound promoting azomethine solution in an enzyme
6 independent reaction and selected from the group consisting of 5-
7 hydroxymethylfurfural, dehydroascorbic acid, malt and vanillin,
8 whereby preferably the mass ratio of the ketoglutaric acid to the
9 at least azomethine formation promoting compound is greater than
10 1:1 , ~~especially 2:1 to 12:1, characterized in that wherein~~ the
11 therapeutic agent contains as further therapeutically effective
12 ~~substances ingredients:~~ N-acetyl-seleno-L-methionine and N-acetyl-
13 L-methionine whereby the latter is present in excess with respect
14 to the former.

1 2. (currently amended) The therapeutic agent according
2 to claim 1 characterized in that the mass ratio of alpha-
3 ketoglutaric acid to N-acetyl-seleno-L-methionine is 100:1 to
4 20000:1 , ~~preferably 500:1 to 10000:1.~~

1 3. (currently amended) The therapeutic agent according
2 to claim 1 ~~characterized in that wherein~~ the mass ratio of N-
3 acetyl-seleno-L-methionine is 20:1 to 300:1 , ~~preferably 50:1 to~~
4 100:1.

1 4. (currently amended) The therapeutic agent according
2 to claim 1 ~~characterized in that~~ wherein it ~~additionally contains~~
3 further comprises glucose, fructose or a mixture thereof.

1 5. (currently amended) The therapeutic agent according
2 to claim 1 ~~characterized in that~~ wherein the compound promoting
3 azomethionine formation is 5-hydroxymethylfurfural.

1 6. (currently amended) The therapeutic agent according
2 to claim 1, ~~characterized in that~~ wherein it is put up in an
3 aqueous solution and the N-acetyl-seleno-L-methionine is present in
4 an amount of 1.4 to 2.3 mg/l and the N-acetyl-L-methionine is
5 present in an amount of 70 to 230 mg/l.

1 7. (currently amended) The therapeutic agent according
2 to claim 1 ~~characterized in that~~ claim 4 wherein it contains an
3 electrolyte from the group of sodium or potassium.

1 8. (currently amended) The therapeutic agent according
2 to claim 1 ~~characterized in that~~ wherein it is administered
3 intravenously and has a pH value of 4 to 6.

1 9. (currently amended) The therapeutic agent according
2 to claim 4 or claim 7 ~~characterized in that~~ wherein the alpha-
3 ketoglutaric acid is present in a concentration of 3 to 20 g/l, the

5 hydroxymethylfurfural ~~[[is]]~~ present in a concentration of 1 to 3
6 g/l, the glucose is present in a concentration of 20 to 100 g/l,
7 the sodium ion is present in a concentration of 60 to 160 mmol/l
8 and the potassium ion is present in a concentration of 15 to 40
9 mmol/l.

1 10. (currently amended) The therapeutic agent according
2 to claim 9 ~~characterized in that~~ wherein the alpha-ketoglutaric
3 acid is present in a concentration of 6 to 16 g/l, 5-
4 hydroxymethylfurfural is present in a concentration of 1 to 2.5
5 g/l, the glucose in a concentration of 20 to 50 g/l, the sodium ion
6 in a concentration of 70 to 160 mmol/l and the potassium ion is
7 present in a concentration of 20 to 40 mmol/l.

1 11. (previously presented) The therapeutic agent
2 according to claim 1 which is put up in a solid or liquid or oral
3 or rectal administration dosage form which contains the
4 ketoglutaric acid at least in part in the form of a monosodium or
5 monopotassium salt thereof.

1 12. (currently amended) The therapeutic agent according
2 to claim 11 which ~~contains~~ further comprises a lubricating agent
3 and/or extender and/or a taste improving disaccharide, ~~especially~~
4 ~~sifted~~ sugar.

1 13. (currently amended) The therapeutic agent according
2 to claim 11 which contains comprises in the dosage unit 3 to 9 g of
3 alpha-ketoglutaric acid, 0.5 to 1.5 g 5-hydroxymethyl-furfural, 1.4
4 to 2.3 mg N-acetyl-seleno-L-methionine and 70 to 230 mg of
5 N-acetyl-L-methionine.

1 14. (currently amended) A method of making a
2 therapeutic agent in a form suitable for intravenous administration
3 according to claim 8 ~~characterized in that~~ wherein the alpha-
4 ketoglutaric acid is dissolved at elevated temperature in distilled
5 water which has had its oxygen content reduced by a gasification
6 and glucose or fructose added to it together with alkalies other
7 than ammonia or amines, the pH being adjusted to be somewhat above
8 4 and N-acetyl-seleno-L-methionine, N-acetyl-L-methionine and the
9 compound promoting azomethine formation.

1 15. (currently amended) A method of making a
2 preparation suitable for oral or rectal administration according to
3 claim 11 ~~characterized in that~~ wherein to adjust the pH from 3 to 6
4 the ketoglutaric acid is partly to entirely used in the form of its
5 monosalt with sodium and/or potassium and in which extenders and if
6 desired also disaccharides are mixed therewith and to this mixture
7 the compound promoting azomethine formation, the N-acetyl-seleno-L-
8 methionine and the N-acetyl-L-methionine are added whereupon the
9 mixture is put up in the desired form of administering especially
10 as a particule granulate, in tablets, or in an irrigating liquid.

16. (canceled)

17. (canceled)

1 18. (New) A cytocidal method of treating a malignant
2 tumor in a patient afflicted with said malignant tumor which
3 comprises the step of administering to said patient, an amount of
4 the therapeutic agent defined in claim 1, effective to treat the
5 malignant tumor.

1 19. (New) The cytocidal method of treating a malignant
2 tumor defined in claim 18 wherein the therapeutic agent is
3 administered to the patient orally, rectally, in the form of an
4 irrigation, or as an intravenous infusion.

1 20. (New) The cytocidal method of treating a malignant
2 tumor defined in claim 19 wherein the therapeutic agent is
3 administered to the patient as an intravenous infusion.

1 21. (New) A therapeutic agent for the cytocidal
2 treatment of a malignant tumor administrable as an intravenous
3 infusion, which consists essentially of:

4 alpha-ketoglutaric acid	6 - 16 g/l
5 5-hydroxymethylfurfural	1.0 - 2.5 g/l
6 N-acetyl-seleno-L-methionine	1.4 - 2.3 mg/l

7 N-acetyl-L-methionine 70 - 230 mg/l
8 glucose 20 - 50 g/l
9 sodium ion 70 - 160 mmol/l and
10 potassium ion 20 - 40 mmol/l
11 in combination with a pharmaceutically acceptable inert carrier
12 suitable for intravenous administration.

1 22. (New) A cytocidal method of treating a malignant
2 tumor in a patient afflicted with said malignant tumor which
3 comprises the step of administering to said patient, by intravenous
4 infusion, an amount of the therapeutic agent defined in claim 21,
5 effective to treat the malignant tumor.